In a study conducted on ApoE(−/−) knockout mice with HFD, when Empagliflozin was administered, it was found that total cholesterol and TGL values were reduced, along with reduced expression levels of lipogenic enzymes such as fatty acid synthase (FAS), sterol regulatory element-binding protein-1 (SREBP-1), and phosphoenolpyruvate carboxykinase-1 (PEPCK-1) compared to control groups, potentially alleviating NAFLD [190]. Here, PCK1 is linked to metabolic dysfunction-associated steatotic liver disease.